Abstract
Forty-five cases of fungaemia due non-albicans Candida spp. (NAC) in a single National Cancer Institution within 10 years were analysed for aetiology, risk factors and outcome. There had been 12 cases of fungaemia that were due to C. krusei, 14 due to C. parapsilosis, 7 due to C. (T.) glabrata, 6 to C. tropicalis, 2 to C. guillermondii, 2 to C. lusitaniae, 1 to C. stellatoidea, and 1 to C. rugosa. Comparison of 45 NAC fungaemia with 75 episodes of C. albicans fungaemia revealed differences only in two risk factors: previous empiric therapy with amphotericin B (16.0 vs 2.2%, P<0.01) appeared more frequently in cases of C. albicans fungaemia, and prior prophylaxis with fluconazole (8.9 vs 0%, P<0.02) was conversely more frequently observed with NAC. The incidence of other risk factors, such as underlying disease, chemotherapy, antibiotic prophylaxis or therapy, treatment with corticosteroids, catheter insertion, mucositis, cytotoxic chemotherapy, and neutropenia, was similar in both groups. There was no difference either in attributable or in overall mortality between NAC and C. albicans fungaemia in our cancer patients.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Published online: 19 August 1999 Some of the information in this paper was presented at the IDSA Annual Meeting (abstracts 355 and 588) held in Denver, 9–11 November 1998
Rights and permissions
About this article
Cite this article
Krcmery Jr., V., Mrazova, M., Kunova, A. et al. Nosocomial candidaemias due to species other than Candida albicans in cancer patients . Support Care Cancer 7, 428–431 (1999). https://doi.org/10.1007/s005200050304
Issue Date:
DOI: https://doi.org/10.1007/s005200050304